Background

There is currently a need for better treatment options for viruses such as HSV and SARSCoV-2. For example, herpes simplex virus (HSV) is a common virus that exists in approximately 90% of the population worldwide. Although clinical expression of this virus can vary, HSV carriers risk developing herpes labialis, also known as cold sores. Cold sores have an average incidence of 1.6 per 1000 patients per year and about one third of all infected patients experience relapse.

Technology Overview

A novel antiviral agent with potent and selective antiviral activity to target herpes simplex virus type 1 (HSV-1) and SARSCoV-2 has been discovered by researchers at McMaster University. This unique small molecule can be used in the treatment of DNA